| Date | Form | Description | Docs | XBRL | Pages |
| 12/07/16 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
138 | |
| 12/23/15 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
97 |
| 01/29/15 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
15 | |
| 01/29/15 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
101 |
| 04/16/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
41 | |
| 01/17/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
|
6 |
| 01/16/14 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
111 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
Latest News & Events
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Read More...Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Read More...